Drug and solute transporters in mediating resistance to novel therapeutics in multiple myeloma
Date
2021
Authors
Mynott, R.L.
Wallington Beddoe, C.T.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
ACS Pharmacology and Translational Science, 2021; 4(3):1050-1065
Statement of Responsibility
Conference Name
Abstract
Multiple myeloma remains an incurable malignancy of plasma cells. Novel therapies, notably proteasome inhibitors and immunomodulatory drugs, have improved the survival of multiple myeloma patients; however, patients either present with, or develop resistance to, these therapies. Resistance to traditional chemotherapeutic agents can be caused by cellular drug efflux via adenosine triphosphate (ATP)-binding cassette (ABC) transporters, but it is still not clear whether these transporters mediate resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Solute carrier (SLC) transporters also play a role in cancer drug resistance due to changes in cell homeostasis caused by their abnormal expression and changes in the solutes they transport. In this review, we evaluate resistance to novel therapies used to treat multiple myeloma, as mediated by drug and solute transporters.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2021 American Chemical Society